US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.17 +0.43 (+2.18%)
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates ↗
Via Chartmill
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals ↗
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗
Via Chartmill
News headline image
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
Via MarketMinute
Topics Intellectual Property
News headline image
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study. 
Via Stocktwits
News headline image
ACADIA (ACAD) Q4 2025 Earnings Call Transcript ↗
ACADIA (ACAD) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug ↗
The company said that the Committee for Medicinal Products for Human Use informed it of a negative trend around its application after an oral explanation recently. 
Via Stocktwits
News headline image
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout ↗
ACADIA Pharmaceuticals shows strong earnings momentum and a bullish technical setup, presenting a potential breakout opportunity for growth investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >